Brief: Anpac Bio-Medical Science Co Sees FY 2020 Revenue Up About 100%
25/11/2020 12:38
Nov 25 (Reuters) - AnPac Bio-Medical Science Co Ltd
ANPC.O :
* SEES FY 2020 REVENUE UP ABOUT 100 PERCENT
* CO'S CANCER SCREENING TESTS' AVERAGE SELLING PRICE IN 2020
IS
EXPECTED TO INCREASE COMPARED TO 2019
* FORECASTS A REVENUE GROWTH OF ABOUT 100% IN 2020 OVER
2019, WITH
A REVENUE RANGE OF US$3 MILLION TO US$3.3 MILLION
Source text for Eikon: ID:nGNX2nZDdt
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022